Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells 2,174 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 2,174 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $46.65, for a total transaction of $101,417.10. Following the completion of the transaction, the insider directly owned 113,549 shares in the company, valued at $5,297,060.85. The trade was a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Wednesday, May 6th, Jula Inrig sold 311 shares of Travere Therapeutics stock. The shares were sold at an average price of $43.95, for a total transaction of $13,668.45.
• On Monday, May 4th, Jula Inrig sold 20,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $45.00, for a total transaction of $900,000.00.
• On Wednesday, April 15th, Jula Inrig sold 1,018 shares of Travere Therapeutics stock. The shares were sold at an average price of $42.61, for a total transaction of $43,376.98.
• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The shares were sold at an average price of $41.93, for a total transaction of $302,524.95.

Travere Therapeutics Stock Performance

Shares of TVTX traded down $0.10 during trading hours on Wednesday, hitting $44.70. The company had a trading volume of 2,390,035 shares, compared to its average volume of 2,890,153. The firm has a market cap of $4.16 billion, a price-to-earnings ratio of -194.33 and a beta of 1.13. The business has a fifty day moving average of $32.59 and a 200-day moving average of $32.83. Travere Therapeutics, Inc. has a 12 month low of $13.88 and a 12 month high of $48.61. The company has a quick ratio of 2.70, a current ratio of 3.13 and a debt-to-equity ratio of 3.16.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business had revenue of $127.20 million for the quarter, compared to the consensus estimate of $136.23 million. During the same period in the prior year, the company posted ($0.47) earnings per share. Travere Therapeutics’s revenue was up 55.6% compared to the same quarter last year. Equities analysts anticipate that Travere Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Travere Therapeutics

Hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new stake in shares of Travere Therapeutics in the 2nd quarter valued at approximately $33,000. Fifth Third Bancorp acquired a new stake in shares of Travere Therapeutics in the 1st quarter valued at approximately $35,000. First Horizon Corp acquired a new stake in shares of Travere Therapeutics in the 3rd quarter valued at approximately $36,000. State of Wyoming acquired a new stake in shares of Travere Therapeutics in the 4th quarter valued at approximately $37,000. Finally, Torren Management LLC acquired a new stake in shares of Travere Therapeutics in the 4th quarter valued at approximately $38,000.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a “buy” rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an “overweight” rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a “Buy” and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on TVTX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. TD Cowen upped their price target on shares of Travere Therapeutics from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday. Citigroup upped their price target on shares of Travere Therapeutics from $53.00 to $59.00 and gave the company a “buy” rating in a research note on Tuesday. Wedbush upped their price target on shares of Travere Therapeutics from $53.00 to $55.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Wells Fargo & Company upped their price target on shares of Travere Therapeutics from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $47.83.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.